- In December 2023, Roche signed a USD 2.7 billion cash agreement to acquire the U.S.-based Carmot Therapeutics. This acquisition strengthens Roche's position in the biotechnology sector. The deal is expected to enhance Roche's drug discovery capabilities, particularly in the areas of oncology and immunology
- In February 2021, Medtronic launched the TYRX Absorbable Antibacterial Envelope, designed to support implanted neurostimulators and cardiac implantable electrical devices. This one-time use envelope offers antimicrobial properties to reduce infection risks. It aims to enhance the safety and longevity of these medical implants by providing an additional layer of protection
Frequently Asked Questions
The market is segmented based on Segmentation, By Product (Structural Cardiac Implants, Stents and Related Implants, and A Pacing Device), Disease (Myocardial Ischemia, Acute Myocardial Infarction, Arrhythmias, Congestive Heart Failure (CHF), Angina Pectoris (AP), Cardiomyopathy, Aortic Aneurism, and Others), Procedure (Angioplasty, Heart Valve Repair or Replacement, Open Heart Surgery, Minimally Invasive Heart Surgery, Cardiac Resynchronization Therapy (CRT), and Others) – Industry Trends and Forecast to 2032
.
The Global Cardiac Bio Implant Devices Market size was valued at USD 55.08 USD Billion in 2024.
The Global Cardiac Bio Implant Devices Market is projected to grow at a CAGR of 10.22% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
